大型人群队列研究中2型脱碘酶Thr92Ala多态性对甲状腺激素参数、健康相关生活质量及认知功能无影响
在LifeLines队列研究的12625名参与者中,评估2型脱碘酶Thr92Ala多态性(rs225014)对甲状腺激素参数、健康相关生活质量及认知功能的影响,并在364名接受甲状腺激素替代治疗者中进行分析。结果显示,无论一般人群还是替代治疗者,该多态性均与促甲状腺激素、游离甲状腺素、游离三碘甲状腺原氨酸、fT3/fT4比值、代谢综合征、健康相关生活质量及认知功能无关。
要点
- 在一般人群和甲状腺激素替代治疗者中,D2-Thr92Ala多态性与甲状腺激素参数均无关。
- 该多态性与健康相关生活质量和认知功能无关。
- 在364名替代治疗者中,Ala/Ala基因型频率为11.3%,一般人群为10.7%。
核心结论
- 在一般人群和接受甲状腺激素替代治疗的参与者中,2型脱碘酶Thr92Ala多态性与甲状腺参数、健康相关生活质量和认知功能无关。
研究设计与样本
- 研究纳入来自LifeLines队列研究、具有全基因组遗传数据的12625名参与者,评估Thr92Ala多态性(rs225014)在一般人群及364名接受甲状腺激素替代治疗者(主要因原发性甲状腺功能减退)中的影响。
主要发现
- LT4使用者平均年龄为53±12岁,体重指数为27.0±4.5 kg/m2;一般人群分别为48±11岁和26.2±4.1 kg/m2。
- LT4使用者中Ala/Ala基因型占11.3%,一般人群中占10.7%。
- 4479名有甲状腺激素数据的受试者中,3742名促甲状腺激素正常(0.4-4.0 mIU/L),88%的LT4使用者为女性。
- LT4使用者游离甲状腺素较高、游离三碘甲状腺原氨酸较低、fT3/fT4比值较低;女性LT4使用者在身体功能、活力、心理健康、社会功能、躯体疼痛和总体健康等生活质量领域评分低于未使用者(p < 0.005)。
- 女性LT4使用者与一般人群的执行功能评分相当;两组中D2-Thr92Ala多态性均与促甲状腺激素、游离甲状腺素、游离三碘甲状腺原氨酸、fT3/fT4比值、代谢综合征或其他合并症、药物使用、健康相关生活质量及认知功能无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The presence of the Thr92Ala polymorphism of deiodinase-2 (D2) has been thought to have several effects. It may influence its enzymatic function, is associated with increased expression of genes involved in oxidative stress in brain tissue, and may predict favorable response to combination levothyroxine (LT4) plus triiodothyronine (T3) therapy. It was hypothesized that homozygous carriers of the D2-92Ala allele have different thyroid hormone parameters, and reduced health-related quality of life (HRQoL) and cognitive functioning. METHODS: In 12,625 participants from the LifeLines cohort study with genome-wide genetic data available, the effects of the Thr92Ala polymorphism (rs225014) were evaluated in the general population and in 364 people treated with thyroid hormone replacement therapy, the latter mainly because of primary hypothyroidism. In addition to evaluating anthropometric data, medication use, and existence of metabolic syndrome, HRQoL was assessed with the RAND 36-Item Health Survey, and the Ruff Figural Fluency Test was used as a sensitive test for executive functioning. Data on thyrotropin, free thyroxine (fT4), and free T3 (fT3) levels were available in a subset of 4479 participants. RESULTS: The mean age (±standard deviation) was 53 ± 12 years and the body mass index was 27.0 ± 4.5 kg/m2 in the LT4 users compared with 48 ± 11 years and 26.2 ± 4.1 kg/m2 in participants from the general population. The Ala/Ala genotype of the D2-Thr92Ala polymorphism was present in 11.3% of LT4 users and in 10.7% of the general population. In total, 3742/4479 subjects with thyroid hormone data available had normal TSH (0.4-4.0 mIU/L), and 88% of LT4 users were females. LT4 users had higher fT4, lower fT3, and a lower fT3/fT4 ratio, and female patients had lower scores on the HRQoL domains of physical functioning, vitality, mental health, social functioning, bodily pain, and general health compared with those not using LT4 (p < 0.005). Executive functioning scores, as part of cognitive functioning, were comparable between female LT4 users and the general population. In both groups, the D2-Thr92Ala polymorphism was not associated with differences in TSH, fT4, fT3, the fT3/fT4 ratio, presence of metabolic syndrome or other comorbidities, use of medication, HRQoL, and cognitive functioning. CONCLUSION: The Thr92Ala polymorphism of D2 was not associated with thyroid parameters, HRQoL, and cognitive functioning in the general population and in participants on thyroid hormone replacement therapy.
引用
- Wouters HJ, van Loon HC, van der Klauw MM, et al. No Effect of the Thr92Ala Polymorphism of Deiodinase-2 on Thyroid Hormone Parameters, Health-Related Quality of Life, and Cognitive Functioning in a Large Population-Based Cohort Study. Thyroid. 2016. PMID: 27786042. doi:10.1089/thy.2016.0199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。